- 40
- 32 916
Cereno Scientific
Sweden
เข้าร่วมเมื่อ 15 ธ.ค. 2021
Cereno Scientific is a Swedish-based clinical-stage biotech company in cardiovascular disease. The company focuses on developing innovative treatments for patients affected by common and rare cardiovascular diseases. Cereno's portfolio of clinical and preclinical drug candidates has the potential to completely change the way cardiovascular disease is treated today.
Cereno Scientific's Capital Markets Day 2024
Cereno Scientific's Capital Markets Day, 17th of October, 2024, at Posthuset in Stockholm.
00:00:00 Welcome
00:00:31 Introduction to Cereno Scientific
00:11:30 Understanding PAH, a debilitating rare disease
00:31:10 Cereno Scientific’s CS1 in PAH
00:38:03 Cereno Scientific’s CS1 - Phase IIa trial results
01:06:35 Investigator and patient perspective of CS1-003 trial
01:16:24 Next steps for CS1
01:20:10 Introduction to Fluidda and the innovative Functional Respiratory Imaging technology
01:39:07 CS014 targeting unmet needs in rare disease IPF
01:53:58 CS585 being evaluated in rare diseases
02:11:52 Cereno Scientific - strategic focus and future outlook
02:26:05 Questions from Audience on site and online
02:46:25 Concluding remarks
00:00:00 Welcome
00:00:31 Introduction to Cereno Scientific
00:11:30 Understanding PAH, a debilitating rare disease
00:31:10 Cereno Scientific’s CS1 in PAH
00:38:03 Cereno Scientific’s CS1 - Phase IIa trial results
01:06:35 Investigator and patient perspective of CS1-003 trial
01:16:24 Next steps for CS1
01:20:10 Introduction to Fluidda and the innovative Functional Respiratory Imaging technology
01:39:07 CS014 targeting unmet needs in rare disease IPF
01:53:58 CS585 being evaluated in rare diseases
02:11:52 Cereno Scientific - strategic focus and future outlook
02:26:05 Questions from Audience on site and online
02:46:25 Concluding remarks
มุมมอง: 10 898
วีดีโอ
Cereno Scientific presents positive topline results of Phase IIa trial with CS1 in PAH
มุมมอง 4Kหลายเดือนก่อน
Cereno Scientific presents positive topline results of Phase IIa trial with CS1 in PAH
Dr. Michael Holinstat presents new preclinical data for CS585 at ESC Congress 2024
มุมมอง 3102 หลายเดือนก่อน
Dr. Michael Holinstat presents new preclinical data for CS585 at ESC Congress 2024
Cereno Scientific at ESC 2024
มุมมอง 8252 หลายเดือนก่อน
Cereno Scientific are at the ESC Congress in London, organized by the European Society of Cardiology. This is the most important congress of the year, where 35 000 people meet with a common goal to improve the lives of people suffering from cardiovascular disease.
Insights Series S3E9: Cereno leading the way in HDAC inhibitors for CVD
มุมมอง 4687 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S3E8: Dr. Björn Dahlöf on HDAC inhibitors as an important potential therapy for CVD
มุมมอง 3397 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S3E7: Dr. Raymond Benza on Pulmonary Arterial Hypertension - Cereno at PVRI
มุมมอง 3338 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Life Sciencedagen 2024
มุมมอง 5308 หลายเดือนก่อน
Cereno presented at Life Sciencedagen, March 6 2024, in Gothenburg CEO Sten R. Sörensen and CMO and Head of R&D Rahul Agrawal, presented the company portfolio, the role of HDAC inhibition and disease-modifying properties of CS1 in PAH, gave an overview of thrombosis prevention with CS014, and an introduction to the preclinical program CS585.
Insights Series S3 E6: Dr. Raymond Benza on HDAC inhibition in PAH
มุมมอง 3688 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insight Series S3 E5: Dr. Raymond Benza on Compassionate Use
มุมมอง 5138 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S3 E4: CEO Sten R. Sörensen about the future implications for PAH patients
มุมมอง 4539 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S3 E3: CEO Sten R. Sörensen on the exciting field of PAH
มุมมอง 4019 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S3 E2: CEO Sten R. Sörensen on “Compassionate use”
มุมมอง 4389 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S3 E1: CEO Sten R. Sörensen about the latest news for Cereno Scientific
มุมมอง 4599 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S2E8: Prof Benza about the move towards innovative trial designs in PAH studies
มุมมอง 6149 หลายเดือนก่อน
Raymond L. Benza, Chief of Pulmonary Hypertension at Mount Sinai Health System, New York City, Principal Investigator of the Phase II study of CS1, and member of Cereno’s Scientific Advisory Board, speaks about how the industry moves toward innovative trial designs in pulmonary arterial hypertension (PAH) studies. English subtitles are available. This video is episode 8 in the Insights Series s...
Insights Series S2E7: Prof Benza about the rationale and design of a Phase II clinical trial in PAH
มุมมอง 58210 หลายเดือนก่อน
Insights Series S2E7: Prof Benza about the rationale and design of a Phase II clinical trial in PAH
Insights Series S2E6: P.Adamson, Abbott, on enhancing quality of life for patients with CardioMEMS™
มุมมอง 38811 หลายเดือนก่อน
Insights Series S2E6: P.Adamson, Abbott, on enhancing quality of life for patients with CardioMEMS™
Insights Series S2E5: Phil Adamson, Abbott, about personalized medicine in PAH with CardioMEMS™
มุมมอง 468ปีที่แล้ว
Insights Series S2E5: Phil Adamson, Abbott, about personalized medicine in PAH with CardioMEMS™
Insights Series S2E4: Phil Adamson, Abbott, about CardioMEMS™ use in the CS1 clinical trial
มุมมอง 433ปีที่แล้ว
Insights Series S2E4: Phil Adamson, Abbott, about CardioMEMS™ use in the CS1 clinical trial
Insights Series S2E3: P.Adamson, Abbott, on CardioMEMS and its utility in the study of heart failure
มุมมอง 381ปีที่แล้ว
Insights Series S2E3: P.Adamson, Abbott, on CardioMEMS and its utility in the study of heart failure
Insights Series S2E2: Prof. Benza about why CS1 is such an exciting drug candidate in PAH
มุมมอง 705ปีที่แล้ว
Insights Series S2E2: Prof. Benza about why CS1 is such an exciting drug candidate in PAH
Insights Series S2E1: Prof. Benza on remarkable patient case study data from Phase II study of CS1
มุมมอง 1.2Kปีที่แล้ว
Insights Series S2E1: Prof. Benza on remarkable patient case study data from Phase II study of CS1
Cereno Scientific's Capital Markets Day 2023
มุมมอง 2.3Kปีที่แล้ว
Cereno Scientific's Capital Markets Day 2023
Cereno at ESC 2023: Our CEO speaks about the latest updates in our Phase II study of CS1 in PAH.
มุมมอง 349ปีที่แล้ว
Cereno at ESC 2023: Our CEO speaks about the latest updates in our Phase II study of CS1 in PAH.
ESC 2023 congress: Sten R. Sörensen, CEO, shares his take on the hottest news in Cereno right now
มุมมอง 117ปีที่แล้ว
ESC 2023 congress: Sten R. Sörensen, CEO, shares his take on the hottest news in Cereno right now
ESC 2023 congress: Our CMO Björn Dahlöf about the great opportunities that the congress brings
มุมมอง 97ปีที่แล้ว
ESC 2023 congress: Our CMO Björn Dahlöf about the great opportunities that the congress brings
Cereno at the ESC 2023 congress! Our CEO Sten R. Sörensen talks about the congress.
มุมมอง 93ปีที่แล้ว
Cereno at the ESC 2023 congress! Our CEO Sten R. Sörensen talks about the congress.
Insights Series: PAH and CardioMEMS collaboration from Abbott's perspective
มุมมอง 213ปีที่แล้ว
Insights Series: PAH and CardioMEMS collaboration from Abbott's perspective
Insights Series: Prof. Benza about Cereno's Clinical Phase II Trial with CS1
มุมมอง 232ปีที่แล้ว
Insights Series: Prof. Benza about Cereno's Clinical Phase II Trial with CS1
It looks pretty good but now it is up to proof now if those who pay (the shareholders) will get any dividends.
These videos are fantastic! Thank you so much! I have shared your channel with the Facebook group for Pulmonary Hypertension Association Australia. I'm so hopeful for CS1!
Som aktieägare är jag otroligt glad över de senaste CS1-resultaten! Och vilka framsteg ni gör inom behandling av kardiovaskulära och sällsynta sjukdomar. Det känns fantastiskt att vara en del av den här resan. Ert strategiska arbete ger mig fullt förtroende för min investering och framtiden ser ljus ut. Keeping my shares 🤝
Amazing CS1 results, this is a huge win for future treatments.Keep pushing the boundaries, this is just the beginning!
Outstanding achievements and impressive results presented! Your relentless dedication to advancing cardiovascular and rare diseases, especially with CS1, is truly commendable. The recent clinical data highlights the potential for life-changing impacts, and it’s inspiring to see your commitment to innovation in a field that affects so many lives. The breakthroughs you’re working toward offer hope to countless patients, and your team's hard work continues to push the boundaries of what's possible in medical science. Keep up the fantastic work!
Congratulations to Cereno for your incredible dedication and hard work! The progress you're making is truly inspiring, and it's amazing to see the impact you're having in the Biotech field. Keep up the great work, we're all cheering you on!
Great video!
big potential here to become the next big swedish biotech
Cereno will achieve great things! What a company!👍
Congratulations on achieving such an impressive result and delivering an outstanding presentation. 🫁
🚀
Cereno is pure gold!!
Cereno fast launch in indian
super duper
Go Cereno!
promo sm 😚
Awesome!
I belive Cereno is on the way to do something great! This is the company that will make an average Joe rich if you play your cards right. That’s just my thoughts. Not to mention the benefit for these ill patients.❤️
🔥🔥
Cereno is future gold!!💪
Go Cereno!
I belive Cs1 is something really unique. Will be exciting to see the result of the study and what a difference it could make for the PAH community.
I’m scare because I have chronic pulmonary artery hypertension 😞
Cereno Scientific @ BioStock Life Science Fall Summit | October 2023 th-cam.com/video/zcSUSAePjZc/w-d-xo.html
The remarkable advancements made with patient one showcase the excellence of this company's state-of-the-art scientific research
🔥
Truly remarkable progress on patient one, this company and its cutting edge science is a true gem!
Interesting video with very strong data from Cereno
remarkable
Amazing as Always!
Would really love if you guys uploaded more information on youtube regarding all three candidates. It really helps getting it on video, with someone explaining.
Hej! Vore tacksamt om ni kunde ladda upp fler klipp och information på er youtube kanal.